Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma A/S proposes sale of 94,000 American Depository Shares. The filing lists a warrant exercise by the issuer for 94,000 ADS on 03/05/2026 with cash consideration. The filing also records prior sales of 86,860 ADS by Jan Moller Mikkelsen on 01/13/2026.
Ascendis Pharma (ASND) Form 144 filing: the filing dated 03/02/2026 lists a planned sale of ordinary shares through Citigroup Global Markets as broker. The filing also records a prior disposition of 10,000 ordinary shares on 12/04/2025 with proceeds of 2,081,018.69. The notice notes restricted stock vesting dated 03/02/2026 in connection with compensation.